RT Journal Article SR Electronic T1 Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6171 OP 6180 DO 10.21873/anticanres.12970 VO 38 IS 11 A1 HYUN MYONG KIM A1 INHYE JEONG A1 HYUN JEONG KIM A1 SUN KYOUNG KANG A1 WOO SUN KWON A1 TAE SOO KIM A1 KYU HYUN PARK A1 MINKYU JUNG A1 JOHN SOONG A1 SHU-CHUAN LIN A1 HYUN CHEOL CHUNG A1 SUN YOUNG RHA YR 2018 UL http://ar.iiarjournals.org/content/38/11/6171.abstract AB Background/Aim: Casein kinase 2 (CK2) is involved in multiple cellular processes. Furthermore, its overexpression in several human cancers has been associated with tumor progression. In this study, we evaluated the efficacy of the CK2 inhibitor, CX-4945, in gastric cancer cell lines and explored the potential predictive biomarkers for CX-4945 sensitivity. Materials and Methods: The sensitivity to CX-4945 was screened in 49 gastric cancer cell lines by the MTT assay. The mRNA and protein expression of CK2 subunits (α and α’) were determined using qRT-PCR and western blot. Furthermore, the activity of CK2α was measured by ELISA. Gene expression and mutations were analyzed via whole-exome and RNA sequencing. Results: The sensitivity to CX-4945 was determined by the inhibition rate (%) at the effective dose (10 μM) which ranged from −1% to 89% in 49 gastric cancer cell lines. CK2α’, but not CK2α, mRNA expression was correlated with CX-4945 sensitivity. Conclusion: In this study, CX-4945 showed modest antitumor efficacy in gastric cancer cell lines. CK2 might represent a potential therapeutic target for gastric cancer.